Significance of Pretreatment C-Reactive Protein, Albumin, and C-Reactive Protein to Albumin Ratio in Predicting Poor Prognosis in Epithelial Ovarian Cancer Patients

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol. 1998;25(3):305–314.
   PubMed Web of Science ®Google Scholar
• Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19(1):3–10. doi:10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S
   PubMedGoogle Scholar
• Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Fuso Nerini I, Cavalieri D, Chiorino G, Cattoretti G, Mangioni C, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer 2013;49(2):520–530. doi:10.1016/j.ejca.2012.06.026
   PubMed Web of Science ®Google Scholar
• Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001;92(9):2399–2405. doi:10.1002/1097-0142(20011101)92:9<2399::AID-CNCR1588>3.0.CO;2-W
   PubMed Web of Science ®Google Scholar
• Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610–618. doi:10.1056/NEJMoa1110352
   PubMed Web of Science ®Google Scholar
• Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol. 2013;23(3):200–207. doi:10.1016/j.semcancer.2013.02.001
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540. doi:10.1016/j.ctrv.2012.08.003
   PubMed Web of Science ®Google Scholar
• Guthrie GJK, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218–230. doi:10.1016/j.critrevonc.2013.03.010
   PubMed Web of Science ®Google Scholar
• Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Eruga B, Ocana A, Tannock IF, Amir E, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–1212. doi:10.1158/1055-9965.EPI-14-0146
   PubMed Web of Science ®Google Scholar
• Clarke SJ, Chua W, Moore M, Kao S, Phan V, Tan C, Charles K, McMillan DC. Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Ther. 2011;90(3):475–478. doi:10.1038/clpt.2011.122
   PubMed Web of Science ®Google Scholar
• Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48(4):155–170. doi:10.3109/10408363.2011.599831
   PubMed Web of Science ®Google Scholar
• Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J. 2010;9:69. doi:10.1186/1475-2891-9-69
   PubMed Web of Science ®Google Scholar
• Ataseven B, Du Bois A, Reinthaller A, Traut A, Heitz F, Aust S, Prader S, Polterauer S, Harter P, Grimm C, et al. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol. 2015;138(3):560–565. doi:10.1016/j.ygyno.2015.07.005
   PubMed Web of Science ®Google Scholar
• Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008;14(3):710–714. doi:10.1158/1078-0432.CCR-07-1044
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen S, Zheng C, Ding M, Zhang L, Wang L, Xie M, Zhou J. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC Cancer 2017;17(1):285. doi:10.1186/s12885-017-3220-x
   PubMed Web of Science ®Google Scholar
• Oriuchi N, Nakajima T, Mochiki E, Takeyoshi I, Kanuma T, Endo K, Sakamoto J. A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients. Jpn J Clin Oncol. 2005;35(7):386–390. doi:10.1093/jjco/hyi109
   PubMed Web of Science ®Google Scholar
• Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56(2):337–344. doi:10.1111/j.0006-341x.2000.00337.x
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow?. Lancet 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0
   PubMed Web of Science ®Google Scholar
• Merritt MA, Rice MS, Barnard ME, Hankinson SE, Matulonis UA, Poole EM, Tworoger SS. Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): A cohort study. Lancet Oncol. 2018;19(8):1107–1116. doi:10.1016/S1470-2045(18)30373-5
   PubMed Web of Science ®Google Scholar
• Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res. 2005;11(19 Pt 1):6966–6971. doi:10.1158/1078-0432.CCR-05-0910
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Fanucchi A, Genazzani AR. Malnutrition and cachexia in ovarian cancer patients: Pathophysiology and management. Anticancer Res. 2001;21(4):2941–2947.
   PubMed Web of Science ®Google Scholar
• Ayhan A, Günakan E, Alyazıcı İ, Haberal N, Altundağ Ö, Dursun P. The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer. Arch Gynecol Obstet. 2017;296(5):989–995. doi:10.1007/s00404-017-4511-9
   PubMed Web of Science ®Google Scholar
• Isobe A, Sawada K, Kinose Y, Ohyagi-Hara C, Nakatsuka E, Makino H, Ogura T, Mizuno T, Suzuki N, Morii E, et al. Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer. PLoS One 2015;10(2):e0118080. doi:10.1371/journal.pone.0118080
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, Sakahara H, Mori T. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997;76(9):1221–1227. doi:10.1038/bjc.1997.537
   PubMed Web of Science ®Google Scholar